Abstract

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.

Keywords

BlockadeMedicineBreast cancerImmune checkpointOncologyPD-L1Internal medicineCancerImmune systemImmunotherapyImmunologyReceptor

Affiliated Institutions

Related Publications

Publication Info

Year
2016
Type
review
Volume
11
Issue
6
Pages
385-390
Citations
30893
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

30893
OpenAlex

Cite This

Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. (2016). PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care , 11 (6) , 385-390. https://doi.org/10.1159/000453569

Identifiers

DOI
10.1159/000453569